Holen Sie sich die Stockscreener-App
84.01
0.39%
-0.33
Handel nachbörslich:
84.01
Schlusskurs vom Vortag:
$84.34
Offen:
$84.12
24-Stunden-Volumen:
624.09K
Relative Volume:
0.59
Marktkapitalisierung:
$6.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-255.84M
KGV:
-19.93
EPS:
-4.2149
Netto-Cashflow:
$-232.60M
1W Leistung:
+6.72%
1M Leistung:
+15.00%
6M Leistung:
+110.97%
1J Leistung:
+159.93%
1-Tages-Spanne:
$83.25
$84.96
1-Wochen-Bereich:
$80.21
$85.94
52-Wochen-Spanne:
$26.20
$85.94
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
84.01 | 6.29B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Hold |
| 2026-01-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - investing.com
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan - Stock Titan
Responsive Playbooks and the APGE Inflection - Stock Traders Daily
APGE Technical Analysis & Stock Price Forecast - Intellectia AI
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - msn.com
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Deutsche Bank Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $118 - Moomoo
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Fairmount Funds Management LLC Increases Stake in Apogee Therape - gurufocus.com
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - Moomoo
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Rankings: Will Apogee Therapeutics Inc benefit from seasonalityEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - za.investing.com
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - investing.com
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat
Mizuho raises Apogee Therapeutics stock price target on AD data By Investing.com - za.investing.com
Mizuho raises Apogee Therapeutics stock price target on AD data - investing.com
Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - Moomoo
Apogee Therapeutics announces $300 million public offering - MSN
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics (APGE) price target increased by 11.74% to 118.86 - MSN
Wolfe Research initiates coverage of Apogee Therapeutics (APGE) with peer perform recommendation - MSN
Insider Sell Alert: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - gurufocus.com
Apogee Therapeutics CFO Henderson sells $170k in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CFO Henderson sells $170k in stock - Investing.com
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - finance.yahoo.com
Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade - Stock Titan
Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up - Stock Titan
Apogee Therapeutics raises $403 million in stock offering By Investing.com - au.investing.com
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics raises $403 million in stock offering - Investing.com
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apogee Therapeutics Inc-Aktie (APGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Apr 01 '26 |
Sale |
84.84 |
5,500 |
466,619 |
208,398 |
| Henderson Jane | Chief Financial Officer |
Apr 01 '26 |
Sale |
85.01 |
2,000 |
170,020 |
177,371 |
| Henderson Jane | Chief Financial Officer |
Mar 25 '26 |
Sale |
85.00 |
2,000 |
170,000 |
179,371 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):